304 related articles for article (PubMed ID: 31933516)
1. Prognostic value of serum microRNA-122 in hepatocellular carcinoma is dependent on coexisting clinical and laboratory factors.
Franck M; Schütte K; Malfertheiner P; Link A
World J Gastroenterol; 2020 Jan; 26(1):86-96. PubMed ID: 31933516
[TBL] [Abstract][Full Text] [Related]
2. Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging.
Gomaa AI; Al-Khatib A; Abdel-Razek W; Hashim MS; Waked I
World J Gastroenterol; 2015 May; 21(18):5654-62. PubMed ID: 25987792
[TBL] [Abstract][Full Text] [Related]
3. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma.
Lee S; Rhim H; Kim YS; Kang TW; Song KD
Liver Int; 2016 Apr; 36(4):580-7. PubMed ID: 26503910
[TBL] [Abstract][Full Text] [Related]
4. The value of the Barcelona Clinic Liver Cancer and alpha-fetoprotein in the prognosis of hepatocellular carcinoma.
Gómez-Rodríguez R; Romero-Gutiérrez M; Artaza-Varasa T; González-Frutos C; Ciampi-Dopazo JJ; de-la-Cruz-Pérez G; Sánchez-Ruano JJ
Rev Esp Enferm Dig; 2012 Jun; 104(6):298-304. PubMed ID: 22738699
[TBL] [Abstract][Full Text] [Related]
5. NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization.
Adhoute X; Pénaranda G; Raoul JL; Bollon E; Pol B; Letreut YP; Perrier H; Bayle O; Monnet O; Beaurain P; Muller C; Hardwigsen J; Lefolgoc G; Castellani P; Bronowicki JP; Bourlière M
Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):706-715. PubMed ID: 28195873
[TBL] [Abstract][Full Text] [Related]
6. Incorporation of alpha-fetoprotein(AFP) into subclassification of BCLC C stage hepatocellular carcinoma according to a 5-year survival analysis based on the SEER database.
Zhang N; Gu J; Yin L; Wu J; Du MY; Ding K; Huang T; He X
Oncotarget; 2016 Dec; 7(49):81389-81401. PubMed ID: 27835609
[TBL] [Abstract][Full Text] [Related]
7. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma.
Köberle V; Kronenberger B; Pleli T; Trojan J; Imelmann E; Peveling-Oberhag J; Welker MW; Elhendawy M; Zeuzem S; Piiper A; Waidmann O
Eur J Cancer; 2013 Nov; 49(16):3442-9. PubMed ID: 23810247
[TBL] [Abstract][Full Text] [Related]
8. Serum miR-224 as a biomarker for detection of hepatocellular carcinoma at early stage.
Lin L; Lu B; Yu J; Liu W; Zhou A
Clin Res Hepatol Gastroenterol; 2016 Sep; 40(4):397-404. PubMed ID: 26724963
[TBL] [Abstract][Full Text] [Related]
9. Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma.
Liu C; Xiao GQ; Yan LN; Li B; Jiang L; Wen TF; Wang WT; Xu MQ; Yang JY
World J Gastroenterol; 2013 Mar; 19(11):1811-9. PubMed ID: 23555170
[TBL] [Abstract][Full Text] [Related]
10. Prognosis evaluation in alpha-fetoprotein negative hepatocellular carcinoma after hepatectomy: comparison of five staging systems.
Zhang XF; Qi X; Meng B; Liu C; Yu L; Wang B; Lv Y
Eur J Surg Oncol; 2010 Aug; 36(8):718-24. PubMed ID: 20538423
[TBL] [Abstract][Full Text] [Related]
11. Serum miR-182 and miR-331-3p as diagnostic and prognostic markers in patients with hepatocellular carcinoma.
Chen L; Chu F; Cao Y; Shao J; Wang F
Tumour Biol; 2015 Sep; 36(10):7439-47. PubMed ID: 25903466
[TBL] [Abstract][Full Text] [Related]
12. Circulating miR-21-5p level has limited prognostic value in patients with hepatocellular carcinoma and is influenced by renal function.
Franck M; Thon C; Schütte K; Malfertheiner P; Link A
World J Hepatol; 2020 Nov; 12(11):1031-1045. PubMed ID: 33312427
[TBL] [Abstract][Full Text] [Related]
13. Circulating miR-148/152 family as potential biomarkers in hepatocellular carcinoma.
Wang F; Ying H; He B; Pan Y; Sun H; Wang S
Tumour Biol; 2016 Apr; 37(4):4945-53. PubMed ID: 26531720
[TBL] [Abstract][Full Text] [Related]
14. Expression of serum miR-218 in hepatocellular carcinoma and its prognostic significance.
Yang L; Xu Q; Xie H; Gu G; Jiang J
Clin Transl Oncol; 2016 Aug; 18(8):841-7. PubMed ID: 26586116
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy.
Pompili M; Rapaccini GL; Covino M; Pignataro G; Caturelli E; Siena DA; Villani MR; Cedrone A; Gasbarrini G
Cancer; 2001 Jul; 92(1):126-35. PubMed ID: 11443618
[TBL] [Abstract][Full Text] [Related]
16. Hepatic miR-126 is a potential plasma biomarker for detection of hepatitis B virus infected hepatocellular carcinoma.
Ghosh A; Ghosh A; Datta S; Dasgupta D; Das S; Ray S; Gupta S; Datta S; Chowdhury A; Chatterjee R; Mohapatra SK; Banerjee S
Int J Cancer; 2016 Jun; 138(11):2732-44. PubMed ID: 26756996
[TBL] [Abstract][Full Text] [Related]
17. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
[TBL] [Abstract][Full Text] [Related]
18. Circulating microRNA-301 as a promising diagnostic biomarker of hepatitis C virus-related hepatocellular carcinoma.
El-Hamouly MS; Azzam AA; Ghanem SE; El-Bassal FI; Shebl N; Shehata AMF
Mol Biol Rep; 2019 Dec; 46(6):5759-5765. PubMed ID: 31471732
[TBL] [Abstract][Full Text] [Related]
19. Alpha-fetoprotein still is a valuable diagnostic and prognosis predicting biomarker in hepatitis B virus infection-related hepatocellular carcinoma.
Yao M; Zhao J; Lu F
Oncotarget; 2016 Jan; 7(4):3702-8. PubMed ID: 26784252
[TBL] [Abstract][Full Text] [Related]
20. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
Caviglia GP; Abate ML; Gaia S; Petrini E; Bosco C; Olivero A; Rosso C; Ciancio A; Pellicano R; Saracco GM; Rizzetto M; Smedile A
Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
